Delivered-To: pgepnewsletter@gmail.com
Received: by 2002:a05:640c:3013:b0:1ee:4bd3:5fc9 with SMTP id z19csp727757eiw;
        Sun, 21 Jan 2024 13:34:20 -0800 (PST)
X-Google-Smtp-Source: AGHT+IHd0WL3FSkqeWy9HwyppUGVfM3FDxQAqxWCpsmLIZh32TBL+MgqbKo9jHTM7dD4XscJKWh3
X-Received: by 2002:a05:622a:348:b0:42a:3ff4:6d9a with SMTP id r8-20020a05622a034800b0042a3ff46d9amr1098569qtw.6.1705872860074;
        Sun, 21 Jan 2024 13:34:20 -0800 (PST)
ARC-Seal: i=1; a=rsa-sha256; t=1705872860; cv=none;
        d=google.com; s=arc-20160816;
        b=ZEIL0lptHq5wsZFE16tmmbpLHlrKsAk6T4PRjt9jTkfe/HWobzn8DvhcXMhJ1wE5Ox
         FxrDdu01L88ch9QOW1faZhqYnMIxo2FZkrCriGktNTVS+ZsGx9oN1axQ1bAnZ94A/L9M
         YEnHG6Cp90kjOtXeXpdchLMPXgwjNmBM+QI7MGCAD2YksSiPHfVteA7IxcOFi/F/ZV7u
         aKFCmSN1lFVeiJp0pu7+3EqvSmzcM5QxMc0rujtNntYVj5pLygJkQtD7zDaLK8hADcqb
         J8jxYdZX1ykIwcSAvC502htDXsL78ZWULISOxIic6DFmdozQQADE1coPe9D0Y7jXN3GC
         Cjug==
ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20160816;
        h=list-unsubscribe:to:reply-to:subject:message-id:mime-version:from
         :date:dkim-signature:dkim-signature;
        bh=xY/2O7qOf9sJcnmdFLXQF/42dKjDulg3u5VdJ+jLDXc=;
        fh=m8+yFGL9AGrkSifADXzxzWHypeMVd9MF7/kbikeN2H4=;
        b=aQ7EwnS3SRq+yrxdSJNisZr3HIxtInY4YJMkW4wg8nepaHfA1i/sOmWxumyv5TDJuD
         DjHMBxNnZ9+71nkZ8igQHU26y9bI+tFXF9yy3fPLHxbWGYKmfatr3fPhlxWxIsYfye+e
         eWjJ5Jk5+IvDKT5IhHCskQVwq2mp1CbcLGRiVV8tNIbBxtvCJ1U/gscqEyNZELLeB3iD
         u+VYLijf5iQ/Xa7u4xpRSGCzTDRrt4ljo9UfT/lFMeTcWE0jufNmmNYVLoLxRsy7t8z3
         SOrKkNdtn/K8/lwcjF6Knrmy26saOiJsyCnWxgwa7qWjN+eY2yxTS9IbhgV3pblw9dC2
         BtkQ==
ARC-Authentication-Results: i=1; mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b=hkOb90bw;
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=YR+f2PX2;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
Return-Path: <bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org>
Received: from xtrwrkzn.outbound-mail.sendgrid.net (xtrwrkzn.outbound-mail.sendgrid.net. [167.89.81.226])
        by mx.google.com with ESMTPS id k12-20020a05622a03cc00b0042a04d87df3si4249517qtx.42.2024.01.21.13.34.19
        for <pgepnewsletter@gmail.com>
        (version=TLS1_3 cipher=TLS_AES_128_GCM_SHA256 bits=128/128);
        Sun, 21 Jan 2024 13:34:20 -0800 (PST)
Received-SPF: pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) client-ip=167.89.81.226;
Authentication-Results: mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b=hkOb90bw;
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=YR+f2PX2;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=isid.org;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=s1; bh=xY/2O7qOf9sJcnmdFLXQF/42dKjDulg3u5VdJ+jLDXc=;
	b=hkOb90bwT2JDkrV+FjBabo3tVlTx9oSRc2/yG8pSz8raO86Phu15PwRbkthe++L+jS2n
	GjZx4ruiGdR5PZ4XDxiZdzm95g4ijNoc//2gPMBzsD9/mKwWON4d3oXNj7EZIMDh+RnpDw
	cJP91nza6F2bWK79SpVdi87fqffm7V61bF/RiAsSK1npqjFm05qmyiq2A8Ha/B+2/rVguL
	10Muxt6NE9q8HSXH3UNHZlbkeRc+DHfKRuXdz81uL2w+3tG+jQlCbvknpqBoLsHWkZwNeM
	SpFIblLmzb7cuQjTdmiFhoMgah6g2vgMNjrp6+ZS1VNa3kth8cQ1LdCRxtzfZqEg==
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=sendgrid.info;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=smtpapi; bh=xY/2O7qOf9sJcnmdFLXQF/42dKjDulg3u5VdJ+jLDXc=;
	b=YR+f2PX2hHJvvaeEvnkkjgb1wd4yP2YahY3d9vyUkG0r931ETPUCYQYI847ERRoYA/yC
	mzqVJ6dUOWva05pskAqOtl1np1wWgtGSjwqXW4YZSgaeQEPcUqmuHSvfZCoL7orq9s7vfc
	2/YgDnXdoawr6gIz0B9ZvVepDwt9Xo4dk=
Received: by filterdrecv-6fc855847c-6hl2f with SMTP id filterdrecv-6fc855847c-6hl2f-1-65AD8DDA-12
        2024-01-21 21:34:18.544634639 +0000 UTC m=+8304745.371391840
Received: from MTkyNjg2NjI (unknown)
	by geopod-ismtpd-13 (SG) with HTTP
	id e991UGmwQnCNa9bBSs7esA
	Sun, 21 Jan 2024 21:34:18.368 +0000 (UTC)
Content-Type: multipart/alternative; boundary=2bd263e9e5b7d43541ca9731e7c0b86c3ccd5a415bd1241747c88d7fefc5
Date: Sun, 21 Jan 2024 21:34:18 +0000 (UTC)
From: ProMED <promed@isid.org>
Mime-Version: 1.0
Message-ID: <e991UGmwQnCNa9bBSs7esA@geopod-ismtpd-13>
Subject: PRO/AH/EDR> COVID-19 update (08): Mongolia (UB) beaver, research,
 2021
Reply-To: noreply@isid.org
X-Feedback-ID: 19268662:SG
X-SG-EID: 
 =?us-ascii?Q?lYKUi1ucKQwcfoVB1xAcbBSlsJP9QSi7ed2VWI0p5NjpCc5BQK+kujBGGO1mU1?=
 =?us-ascii?Q?iBrMOi8tiQm8zRQFvowYVRDxrlo18+J6xeryam3?=
 =?us-ascii?Q?q4dLzYyk3wApAkVlUZ84fVS3JiXK9P7RzKlTKCm?=
 =?us-ascii?Q?+B78mGN+Jom+s9v1k2Y7H=2FaFPMv5QNaXwejE0Q7?=
 =?us-ascii?Q?7aE41LMwhyiJq=2FCbeRu9E+FjxOJ1wckO2ZGRcHz?=
 =?us-ascii?Q?uLCBs7XDIEw198G8MzXRmxpFBDM5bk5zkyjjeG?=
X-SG-ID: 
 =?us-ascii?Q?se=2F49CGmbS0sfR97ImeXvNhg9p9jggtUUChgqoY2wUiShGf=2FO8XJWpH34Od4Nd?=
 =?us-ascii?Q?fxXa6jil96uRcJkF+N+LeVnO1tx80ddOyoyOo=2Fc?=
 =?us-ascii?Q?Brxcl3ERAm0cOY743=2FFH59DWiSf5OzXORh1DLKt?=
 =?us-ascii?Q?hb1NMKty3PsA5ju0ZzxCrq1WQuZSEQf=2FJlWtgqv?=
 =?us-ascii?Q?cZmsyCHlNUZsDVbdq=2FFXPIYFMGhzZjXqaoHUiTI?=
 =?us-ascii?Q?2uaE+lLbhfsODFeK6=2FdYPGfz=2Fayg0MEULEwgNIx?=
 =?us-ascii?Q?PSg73gVrkg80SjGt80bZMAEOrsBvoFt82Gmk1xF?=
 =?us-ascii?Q?pNv1VCYaKWGZMk7PazEu7d60Iu3GzdpGQnknzhj?=
 =?us-ascii?Q?eW07nZZU53Bgy5XrtBWVSAiic1ihulsXgkWxEgx?=
 =?us-ascii?Q?7rTsIyWXTWG+OdAjnngD9n5fpKs31hsORinAOf4?=
 =?us-ascii?Q?ttk72xdfHItuarNBLb0XC34LFWwJw9DAIiD9gRT?=
 =?us-ascii?Q?A5k6+UBXPfB5D4cy+SpZVwviIubVMMe+GWfaujZ?=
 =?us-ascii?Q?K6jzYwRCRYvaN1yFNPCWuz+JI=2FfNMSicbXw90OO?=
 =?us-ascii?Q?zScKZrAlZkomxUFsf=2FRn33Bx=2FjGQkGgIFKGV9xc?=
 =?us-ascii?Q?AamPttcjKbHGMr8Ixd67m5FDDt4o8BQbD5MYY=2FF?=
 =?us-ascii?Q?1gg3kJ6fVG2aV+MJsPc9qJWi7AYjYTaqhxnH2UQ?=
 =?us-ascii?Q?bLZadCYJtpvcyHw8XLn8nyyjmuqdVGWFil53m0C?=
 =?us-ascii?Q?rLpg7H2LgiCTShLHu7wIlTBeCKHYA04ZEp5ymha?=
 =?us-ascii?Q?pC5wUv=2FGlRqSnGceBs6qLGwpM3IRW=2FiqkI0fCIo?=
 =?us-ascii?Q?koayM5MaGw8UGEQ1aal02l1G7w=3D=3D?=
To: pgepnewsletter@gmail.com
X-Entity-ID: 3CKJgmVGbBVD214dsRqreg==
List-Unsubscribe: 
 =?us-ascii?Q?=3Cmailto=3Aunsubscribe=40em7004=2Eisid=2Eorg=3Fsubject=3D19268662=2EjGEQIHRLA?=
 =?us-ascii?Q?8xcvyIGELklotG5yqcDAul3-NRBJVP9L=5FtoMDAw?=
 =?us-ascii?Q?dTAwMPoeE0spIzDiJ7ns38nQJEUaPc20IXLf9Od?=
 =?us-ascii?Q?hos72VZwuS2LeVjyRAVQlz5o9Fc0oYC7gufd=5Fdo?=
 =?us-ascii?Q?Gb8rQCPOt5-7Aa6bKE1aoZUE7P8SYG24a1YnRyY?=
 =?us-ascii?Q?zWZIRwXQAyTJwzfYg=3D=3D=2Eu0Wl-SHm-TsGCCcQnQp?=
 =?us-ascii?Q?cHAzKKYGDOR6=5FDJ9Abacbsn5oMDAwdTAwMJ-iNP?=
 =?us-ascii?Q?OAt05LvNWmU0L2ulcGeC6lTiyjzUmE-aS5qHN3L?=
 =?us-ascii?Q?K-nRjIAwvKWMMH0Yo33FH67UP2BdhGYd21xrSwF?=
 =?us-ascii?Q?WmLtTBezb9kL8ZRg=5Fh5WWdB9AoMWoi2k2MTFdkR?=
 =?us-ascii?Q?cYfYC5w1xRccfOq2rtaXgqu3hP6f0MH1KHNXsGc?=
 =?us-ascii?Q?gX4JwLD0jildZDIb8PohhKJTx37qD7tGSUn1CVW?=
 =?us-ascii?Q?3fiPERUz58=5FXblgCumQHrchaDtW=5FrcSPFrtrQom?=
 =?us-ascii?Q?53BKwEn2qWhBZAVyABDcK3VnaWUZLitnwzMuk5Q?=
 =?us-ascii?Q?joGcregdADFmK6UDN2-mnN4In3d0K6zyHCVyQFs?=
 =?us-ascii?Q?BGB6EXGWCZ8PP-UDHcNBWtZm8-Cbxgu2glOQ9LG?=
 =?us-ascii?Q?4-Wp6VQfInfRp=5Fr0sT1K72YR9L6htw5uBAlWbIx?=
 =?us-ascii?Q?P1Ji8gCS4FNy2EF3HtttYEUWsyxw9CrKjF2gPFm?=
 =?us-ascii?Q?k0skdqjxnz5B5S4F=5FeM-9Pk6RzLY4HBk1oJ6jJs?=
 =?us-ascii?Q?9=5FD7m7CIQZ8DMiMNZP8wG2QMyrxkTe9NN9b6LwQ?=
 =?us-ascii?Q?vYTEV7G8Gl536g8QInZ8=5FiGVMffXhu0NWn591gk?=
 =?us-ascii?Q?hhVDHra4UnsMbLBHm0exybIb2TlkbTBQg1onqHw?=
 =?us-ascii?Q?f4rZC=5FpfqPQjQS=5FHzrynK1o4iIl208kbuRRCI7P?=
 =?us-ascii?Q?go3xxsf2d7TPTIazeTmml57N8uvWeAl3tRdKt2B?=
 =?us-ascii?Q?g03fRw2AmnurcxnPSgv3YwrBJxyGNhare466Dor?=
 =?us-ascii?Q?3eejV0NUoebduyql3Yo6yon-0Vw=5FfsQsUsvXF0k?=
 =?us-ascii?Q?uc716Sq0Z5Hz2cwNlT6d9RhdSKtZI2xIQ8e0kBH?=
 =?us-ascii?Q?gDpbFbr18UYiGS3-2wl9V4DJwQZFOzDO4UGW9q3?=
 =?us-ascii?Q?O--fHRo9lWpjES94cgl1QtDqV2Y3ZN0zL7qPKzF?=
 =?us-ascii?Q?4bbPsx48CpzqYslp3OwP4Bmgqa1F7ANRN9YluZm?=
 =?us-ascii?Q?IMYAxKaMrBWqbWSVyapjlLcOtx4-ZfRwHib42ce?=
 =?us-ascii?Q?rsldTasi3ztLhfg2Luw1f=5F8y5w39191wPGZxGSC?=
 =?us-ascii?Q?gfshiI=5FyHgikCXQTEnb-pJGbP4NVC72F4kcMY4V?=
 =?us-ascii?Q?gUNA-w=3D=3D=3E?=

--2bd263e9e5b7d43541ca9731e7c0b86c3ccd5a415bd1241747c88d7fefc5
Content-Transfer-Encoding: quoted-printable
Content-Type: text/plain; charset=iso-8859-1
Mime-Version: 1.0

CORONAVIRUS DISEASE 2019 UPDATE (08): MONGOLIA (ULAANBAATAR) BEAVER,
RESEARCH, 2021
***************************************************************************=
********
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Sat 20 Jan 2024
Source: CIDRAP (Center for Infectious Disease Research & Policy)
[edited]
<https://www.cidrap.umn.edu/covid-19/researchers-outline-covid-19-outbreak-=
mongolian-beaver-farm>


Yesterday [19 Jan 2024] in Emerging Infectious Diseases
[<https://wwwnc.cdc.gov/eid/article/30/2/23-1318_article>], scientists
describe a 2021 COVID-19 outbreak at a beaver farm in Mongolia.

Located in the Bayanzurkh district in Ulaanbaatar, the farm raised 32
adult beavers and 16 kits in 2021 for conservation purposes. The
animals lived in a large indoor area separated by waist-high walls.

On 6 Aug 2021, one of the 7 farm employees tested positive for
COVID-19 after experiencing flu-like symptoms. Three days later, the
farm reported the death of 2 beavers aged 6 months and 2 years after
they exhibited cough, nasal discharge, rasping sounds in the lungs and
chest, sluggishness, and food aversion.

On 13 Aug 2021, investigators collected nasal swabs, saliva, and
tissue from the 2 dead beavers and obtained nasal samples, saliva, and
blood from 7 other beavers exhibiting cough and nasal discharge with
pus. Later that week and on 12 Sep 2021, the researchers collected
more samples from the same animals and from 2 healthy beavers.

Four unique mutations spark concern
-----------------------------------
Nearly all (46 of 48) specimens from 9 beavers with clinical signs,
including the 2 dead animals, tested positive for COVID-19 on
polymerase chain reaction (PCR) testing. Serologic testing of 23
samples revealed the presence of SARS-CoV-2 antibodies in 15. One
beaver that didn't show signs of infection also had antibodies.

An alarming aspect of SARS-CoV-2 infection in animals is that host
animals can maintain the virus and contribute to the emergence in
humans of new variants that have accumulated multiple mutations.

Five random SARS-CoV-2-positive samples were shipped to Austria for
whole-genome sequencing, which identified the delta variant. The delta
and alpha variants were circulating among people in Mongolia at the
time, and the closest related sequences in the beaver samples were
from human SARS-CoV-2 in Mongolia, although they contained 4 novel
mutations not found in any public databases as of November 2023.

"An alarming aspect of SARS-CoV-2 infection in animals is that host
animals can maintain the virus and contribute to the emergence in
humans of new variants that have accumulated multiple mutations," the
study authors wrote. "Because the emergence of viruses with mutations
not targeted by current SARS-CoV-2 vaccines is a credible possibility,
more active surveillance of SARS-CoV-2 infection in animals should be
encouraged to identify the appearance of mutated viruses."

[Byline: Mary Van Beusekom]

--
Communicated by:
ProMED
via
ProMED-MBDS

[The citation, abstract and full text of the article referenced above
follow:

Takemura T, Ankhanbaatar U, K Settypalli TB, et al. SARS-CoV-2
infection in beaver farm, Mongolia, 2021. Emerg Infect Dis. 2024.
<https://doi.org/10.3201/eid3002.231318>
---------------------------------------------------------------------------=
-----
Abstract
--------
"We report an outbreak of COVID-19 in a beaver farm in Mongolia in
2021. Genomic characterization revealed a unique combination of
mutations in the SARS-CoV-2 of the infected beavers. Based on these
findings, increased surveillance of farmed beavers should be
encouraged." [References, tables, figures, gray boxes and appendices
can be seen at the source URL above]

"The COVID-19 pandemic that began in 2019 remains uncontained, and
fatalities and multiple waves of infection continue to occur worldwide
(1). The causative agent, SARS-CoV-2, has been detected in humans and
several animal species, including domestic, wild, and laboratory
animals (2,3). Because SARS-CoV-2 can be transmitted from humans to
animals and back to humans, understanding the dynamics of infection in
animals can contribute to the creation of more comprehensive response
strategies."

"We identified SARS-CoV-2 infection in beavers (_Castor fiber_) farmed
for conservation reasons in Mongolia and report on serologic and whole
genome sequence data from this outbreak. The beaver farm, located in
the Bayanzurkh district in Ulaanbaatar, Mongolia, reared 32 adults and
16 kits in 2021. They were housed indoors in a large area separated by
waist-high walls, with space for multiple animals. One of the 7
employees of the farm had influenza-like symptoms for several days and
was diagnosed with COVID-19 on 6 Aug 2021. On 9 Aug 2021, the beaver
farm reported the death of 2 beavers (one 6 months of age and one 2
years of age) after signs of coughing, nasal discharge, rasping on
auscultation of the lungs and chest cavity, sluggish movement, and
aversion to food. On 13 Aug 2021 research investigators collected
nasal swabs, saliva, and 7 tissue samples (lung, kidney, liver, heart,
spleen, larynx, and tongue from the 2 dead animals. Researchers also
collected nasal swab specimens, saliva, and blood from 7 other beavers
with notable clinical signs of coughing and purulent nasal discharge.
Follow-up investigation on 18 or 19 Aug 2021 and on 12 Sep 2021
included collection of additional nasal swab specimens, saliva, and
blood samples from the same animals as well as from 2 healthy animals
(12 Sep 2021 only)."

"All samples were transported to a Biosafety Level 3 facility in
Ulaanbaatar and were screened by quantitative reverse transcription
PCR according to the Peiris protocol (4). The results showed that 46
of 48 specimens from 9 animals with clinical signs, including the 2
dead animals, tested positive for SARS-CoV-2 RNA. Serum was separated
from the blood samples by centrifugation (2000 x g for 10 min) and
stored at -20=B0C until required. The serum samples were then subjected
to antibody screening by using a commercial ELISA kit (ID Screen
SARS-CoV-2 Double Antigen Multi-species ELISA; Innovative Diagnostics,
<https://www.innovative-diagnostics.comExternal Link>). Fifteen of 23
samples tested positive and one was intermediate, indicating that all
animals became antibody positive within one month of confirmation of
SARS-CoV-2 RNA positivity. One clinically unremarkable beaver tested
positive for SARS-CoV-2 antibodies, indicating a possible subclinical
infection (Table)."

"Phylogenetic tree of SARS-CoV-2 identified from beavers and humans in
Mongolia (gray boxes) and reference sequences. The circle size
indicates the bootstrap values at the node. The vertical bar shows the
genetic distance. SARS-CoV-2 lineages are identified at right. GenBank
accession numbers and date identified are shown for reference
sequences; the newly obtained sequence data were deposited in GenBank
(accession nos. OR389473-7)."

"We shipped 5 randomly selected quantitative reverse transcription
PCR-confirmed SARS-CoV-2-positive RNA samples to the Animal Production
and Health Laboratory (Seibersdorf, Austria), a joint program of the
International Atomic Energy Agency and the Food and Agriculture
Organization of the United Nations and subjected them to whole-genome
sequencing (Appendix 1; Appendix 2). Based on genotype analysis, all 5
genome sequences were assigned to the B.1.617.2 lineage, commonly
referred to as the delta variant. At the time of sampling, alpha and
delta variants of SARS-CoV-2 were being identified in humans in
Mongolia. The closest related sequences to those we identified in the
beavers studied were from human SARS-CoV-2 in Mongolia (GenBank
accession nos. ON008302, OM190617, and OM961234) identified during
April-September 2021 (Figure). In addition to 4 mutations in the spike
region, the sequences shared 7 amino acid substitutions in open
reading frame [ORF] 1a, 4 amino acid substitutions in ORF1b, and one
amino acid substitution in nucleocapsid genes. In the beaver
sequences, 4 amino acid substitutions identified were not in the human
isolates from Mongolia: S2500F, A3657V in ORF1a and H604Y, T1404M in
ORF1b. Although those substitutions have been identified individually
in SARS-CoV-2 sequences in GenBank and the GISAID database
(<https://www.gisaid.orgExternal Link>), there are no records of
sequences with all 4 mutations."

"Several cases of SARS-CoV-2 transmission between humans and animals
have already been reported (5-8). An alarming aspect of SARS-CoV-2
infection in animals is that host animals can maintain the virus and
contribute to the emergence in humans of new variants that have
accumulated multiple mutations (7-10). Indeed, the specific
combination of mutations observed in the beavers we studied has not
been found in other SARS-CoV-2 sequences in public databases (as of
November 2023). This finding suggests that the mutations might have
occurred or accumulated after the introduction of the virus into the
beaver population. Because the emergence of viruses with mutations not
targeted by current SARS-CoV-2 vaccines is a credible possibility,
more active surveillance of SARS-CoV-2 infection in animals should be
encouraged to identify the appearance of mutated viruses. In
intensively farmed animals, species-species and species-humans contact
is more frequent than in animals dwelling in other environments, which
might increase the risk for zoonotic pathogen transmission (2). Thus,
implementing more active surveillance and infection control strategies
is critical to disease prevention and containment."

An image of beaver can be seen at
<https://www.cidrap.umn.edu/sites/default/files/Beaver.jpg>

The FAO's "SARS-CoV-2 in animals situation update (5 Dec 2023)" is
available at
<https://www.fao.org/animal-health/situation-updates/sars-cov-2-in-animals>=
.
=20
"As the COVID-19 pandemic continues, the number of mammal species that
are susceptible to infection with SARS-CoV-2 increases. We are at the
beginning of a macrocycle that may become the 1st documented case of a
viral infection with exceptional characteristics in terms of
host-range susceptibility. Coronavirus infections in humans find their
origins in viruses circulating in wildlife -- in particular, bats --
through cross-species transmission that often includes intermediate
hosts, such as alpacas, palm civets, rodents, cattle, and dromedary
camels. Overall, the transmission of pathogens is not unidirectional;
ecosystem disruptions and alterations to the human-wildlife interface
also create opportunities for circulating infectious agents to undergo
reverse zoonotic transmission, or spillback, into domestic and wild
animal species."
(<https://academic.oup.com/bioscience/article/73/11/814/7478069>) -
Mod.TTM

ProMED map:
Mongolia: <https://promedmail.org/promed-post?place=3D8714374,1>]

[See Also:
COVID-19 update (07): Bangladesh, JN.1, variant of interest
http://promedmail.org/post/20240120.8714357
COVID-19 update (06): India, decrease in cases
http://promedmail.org/post/20240117.8714284
COVID-19 update (05): Pakistan, JN.1, variant of interest
http://promedmail.org/post/20240111.8714166
COVID-19 update (04): selected locations, JN.1 virology, severity,
omicron BA.4.1 in dogs http://promedmail.org/post/20240111.8714155
COVID-19 update (03): Israel, JN.1, new variant
http://promedmail.org/post/20240104.8714055
COVID-19 update (02): India
http://promedmail.org/post/20240103.8714052
COVID-19 update (01): Cambodia, new JN.1 variant detection
http://promedmail.org/post/20240101.8714020
2023
----
COVID-19 update (39): Saudi Arabia, JN.1 variant, MOH
http://promedmail.org/post/20231222.8713858
COVID-19 update (38): WHO classifies JN.1 coronavirus strain as
'variant of interest' http://promedmail.org/post/20231220.8713808
COVID-19 update (37): vaccine comp., selected regions, circ. variants,
research http://promedmail.org/post/20231219.8713789
COVID-19 update (36): selected countries/regions, vaccines
http://promedmail.org/post/20231212.8713666
COVID-19 update (35): Singapore, increase
http://promedmail.org/post/20231209.8713618
COVID-19 update (34): selected country/region updates, variants, WHO
http://promedmail.org/post/20231130.8713398
COVID-19 update (33): country updates, vaccines, vaccine refusal, WHO
update http://promedmail.org/post/20231105.8713000
COVID-19 update (32): updates, variants, vaccines, antivirals,
scientific literature http://promedmail.org/post/20231026.8712809
COVID-19 update (31): BA.2.86 & EG.5, selected regions, vaccines, WHO,
global http://promedmail.org/post/20231009.8712522
COVID-19 update (30): omicron EG.5.1, updates, WHO, global
http://promedmail.org/post/20230815.8711701
COVID-19 update (29): updates, wastewater surveillance, transmission,
WHO, global http://promedmail.org/post/20230802.8711526
COVID-19 update (28): superspread, masks, vaccination, WHO, global
http://promedmail.org/post/20230724.8711339
COVID-19 update (27): vaccination, test kit distribution, sequelae,
WHO, global http://promedmail.org/post/20230717.8711208
COVID-19 update (26): animal, North America, wild deer as reservoirs
http://promedmail.org/post/20230713.8711124
COVID-19 update (25): vaccines, liver disease, sequelae, WHO, global
http://promedmail.org/post/20230713.8711095
COVID-19 update (24): long-term effects, EU.1.1, wild bat, WHO, global
http://promedmail.org/post/20230704.8710946
COVID-19 update (23): EU transition plan, viral emission, vacc
hesitancy, GBS, WHO http://promedmail.org/post/20230619.8710662
COVID-19 update (22): trends, immunity, children, metformin, WHO
http://promedmail.org/post/20230612.8710546
COVID-19 update (21): countries, life expectancy, long COVID,
research, WHO, global http://promedmail.org/post/20230605.8710423
COVID-19 update (20): countries, Paxlovid, vaccine, WHO
http://promedmail.org/post/20230530.8710317
COVID-19 update (19): countries, vaccine composition, XBB1.16, WHO,
global http://promedmail.org/post/20230522.8710178
COVID-19 update (18): country/regional, vaccine policies, vaccination,
WHO, global http://promedmail.org/post/20230516.8710088
COVID-19 update (17): WHO, USA, India, China, XBB.1.16, research,
global http://promedmail.org/post/20230508.8709926
COVID-19 update (16): XBB.1.16, reinfections, microglia, sequelae,
WHO, global http://promedmail.org/post/20230502.8709789
COVID-19 update (15): India, XBB.1.16, fetal brain damage, HCW, global
http://promedmail.org/post/20230417.8709526
COVID-19 update (14): countries, vaccines, XBB.1.16, long COVID, WHO
http://promedmail.org/post/20230407.8709377
COVID-19 update (13): India, surveillance, HCW, rats, infant
hospitalizations, WHO, global
http://promedmail.org/post/20230329.8709196
COVID-19 update (12): countries, variants, susceptibility, vaccines,
WHO, global http://promedmail.org/post/20230321.8709066
COVID-19 update (11): country responses, complications, treatment,
WHO, global http://promedmail.org/post/20230312.8708900
COVID-19 update (10): Hong Kong, XBB.1.5, Iran, UAE, bivalent vacc
http://promedmail.org/post/20230308.8708776
COVID-19 update (09): XBB.1.5, vaccine, WHO
http://promedmail.org/post/20230228.8708641
COVID-19 update (08): countries, immunity, vaccines, treatment, masks,
WHO, global http://promedmail.org/post/20230219.8708482
COVID-19 update (07): countries, molnupiravir, vaccines, PACS,
cockroach, WHO http://promedmail.org/post/20230212.8708331
COVID-19 update (06): China, demographics, symptoms, PACS, WHO
http://promedmail.org/post/20230204.8708165
COVID-19 update (05): PHEIC continues, WHO
http://promedmail.org/post/20230130.8708059
COVID-19 update (04): PHEIC, China, susp outbreaks, responses,
vaccines, global http://promedmail.org/post/20230130.8708043
COVID-19 update (03): China, guidelines, vacc, immunity, sequelae, WHO
http://promedmail.org/post/20230122.8707910
COVID-19 update (02): China, XBB.1.5, Hong Kong, mAb, pathogenesis,
WHO, global http://promedmail.org/post/20230115.8707786
COVID-19 update (01): China, Hong Kong, XBB.1.5, PAHO, treatment,
testing, WHO http://promedmail.org/post/20230107.8707667
2022
----
COVID-19 update (193): surge, travel restrictions, screening,
treatment, WHO http://promedmail.org/post/20221230.8707528
COVID-19 update (191): omicron BF.7, bivalent vaccines, China, WHO,
global http://promedmail.org/post/20221224.8707437
COVID-19 update (190): China, Australia, vaccines, sequelae, WHO,
global http://promedmail.org/post/20221219.8707306
COVID-19 update (189): mortality, mAb, intranasal vacc, NPIs,
sequelae, WHO, global http://promedmail.org/post/20221209.8707146
COVID-19 update (188): China, omicron BA.2.76, outdoor transmission
http://promedmail.org/post/20221130.8706983
COVID-19 update (187): boosters, omicron BQ.1.1, Asia, Australia, WHO,
global http://promedmail.org/post/20221129.8706920
COVID-19 update (185): chr. COVID, bladder, recovery, renal, deaths,
WHO, global http://promedmail.org/post/20221111.8706665
COVID-19 update (184): vaccination response, disparity, WHO, global
http://promedmail.org/post/20221104.8706549
COVID-19 update (183): cardiac events, exercise, US deaths, boosters,
WHO, global http://promedmail.org/post/20221028.8706414
COVID-19 update (182): frontline workers, life expectancy,
subvariants, WHO, global http://promedmail.org/post/20221021.8706286
COVID-19 update (181): Africa vacc hesitancy, pre-eclampsia, boosters,
nasal vacc, WHO, global http://promedmail.org/post/20221014.8706143
COVID-19 update (180): long COVID, neuropsy. illness, Paxlovid,
subvariants, WHO http://promedmail.org/post/20221007.8706007
COVID-19 update (170): case severity, boosters, physical activity,
WHO, global http://promedmail.org/post/20220825.8705236
COVID-19 update (160): vaccine rollout disparities, smell & taste,
WHO, global http://promedmail.org/post/20220731.8704776
COVID-19 update (150): France, omicron 2nd gen variant, paxlovid, WHO,
global http://promedmail.org/post/20220705.8704255
COVID-19 update (140): Thailand, human to cat to human transmission
http://promedmail.org/post/20220612.8703819
COVID-19 update (130): surveill., cardiac eff., long COVID subtypes,
WHO, global http://promedmail.org/post/20220601.8703606
COVID-19 update (120): N Korea, pandemic exit, youth vaccine, US
deaths, WHO http://promedmail.org/post/20220518.8703327
COVID-19 update (110): mutations, mental health, China, S Africa,
Paxlovid, WHO http://promedmail.org/post/20220505.8703018
COVID-19 update (100): vacc. intervals, deaths, long COVID,
subvariants, global http://promedmail.org/post/20220420.8702717
COVID-19 update (90): strategy, 2nd booster, WHO
http://promedmail.org/post/20220407.8702454
COVID-19 update (80): animal, USA, deer, transmission
http://promedmail.org/post/20220325.8702212
COVID-19 update (70): case count, UK, BA.2, USA, WHO, global
http://promedmail.org/post/20220312.8701940
COVID-19 update (60): animal, China, origin, research
http://promedmail.org/post/20220227.8701690
COVID-19 update (50): Hong Kong, estrogen risk, maternal vaccine
benefits, WHO http://promedmail.org/post/20220217.8701501
COVID-19 update (40): Denmark, rosemary, pregnancy, stroke, WHO
http://promedmail.org/post/20220205.8701276
COVID-19 update (30): variants in immuno-comp., stability, endemic,
WHO http://promedmail.org/post/20220126.8701074
COVID-19 update (20): Africa vacc., Taiwan, waning immunity,
persistence, global http://promedmail.org/post/20220117.8700915
COVID-19 update (10): animal, omicron origin statement, OIE
http://promedmail.org/post/20220110.8700763
COVID-19 update (01): omicron severity & changes, Germany, T-cell
reactivity http://promedmail.org/post/20220101.8700616]
.................................................ttm/st/may/jh
*##########################################################*
************************************************************
ProMED makes every effort to verify the reports that are posted, but the ac=
curacy
and completeness of the information, and of any statements or opinions base=
d
thereon, are not guaranteed. The reader assumes all risks in using informat=
ion
posted or archived by ProMED. ISID and its associated service providers sha=
ll not
be held responsible for errors or omissions or held liable for any damages =
incurred
as a result of use or reliance upon posted or archived material.
************************************************************
Donate to ProMED. Details available at: https://isid.networkforgood.com/pro=
jects/79924-invest-in-the-mission.
************************************************************
Visit ProMED's website at https://www.promedmail.org/.
Submit all items for posting via the ProMED website at https://promedmail.o=
rg/submitinfo/.
If you have any questions or need support, please contact us via the ProMED=
 website at  https://promedmail.org/support/.
You may subscribe/unsubscribe at  https://isid.org/promedmail-subscribe/.
Unsubscribe Preferences ( https://u19268662.ct.sendgrid.net/asm/?user_id=3D=
19268662&data=3DLnf8WbiB-BSp1lEdedFtvk4_L4-E9azacMvmjLpo_DZoMDAwdTAwMKXB3AK=
DS3wbrCkyM-oRVkxES3qkbK321OhJOQmG9dISsyzioppB_TvVXYSn-S9zBFYyw-ygonLgj7t02B=
T-RCEw7eJsp0bQv71l-Sa3tWEr_yA3gHORZ0iNOZ0yXDxglx5U9UetLprx727kzfPvBCHNgdJR-=
7jEGbHwD73th2dqWjxjo1I-C8al_i3O60HDbGYi594qPozBadFk9f-ql_CZ2r9uel3T4s8p_vL8=
WCS63glBEZKAUssX8m1PtXA7Vd1cqC1GGUuNxXu8yG5sx9jN3v3DpPljRs1-ej1-UWHSQLuCT0j=
Ru6jLOiuWs9XD7tSf7c5YflxYTAcqzeMiajaLVvmNiL_u0Fjvl55TBznBsCXcBXbj8WG5zUBAZm=
mLih7NdiCUcjBjVz2DWiHP_FqvKVK3VYtOLRZWCVyvAP4ov3zpmNbCrX6-V-Yw83BK0PfdrxpDO=
sYQx-LrpSiwS9vBd49L7tsJjvEJFsfggjNv4gIW6j1cxqZ73EkysrpC9ovJA57BwrF_UfF1p3P7=
QgtSMP0GADKkt6stvIC5VMsqOoAIkVXMZ-OgBcC9_h_vgCVK6fON9uH2KLApTJjpn5hEUMKQGH-=
RtEDqZjZdicIC_gj4ngBuTfw1a8jzltJj2FzvG5rggvwwiHvJzOlnXUonBuFfqWT5gJWL0D6H_N=
n7EOzycSwzjnaVxTqmKSEiRdBaHiBpsdvXOmOZvTlboM4hUvXK39Tw1b1l3QUyJllGjHBW1iB1Z=
fcEpnpwbb6hA4em8znf__0iJ0BYIpCVzYHa6IZxpOgTJSBUWoaBDUHNhq0PiM-66Sn2cad_9W-2=
buRlwxbYWd9Dm7RvKvFYjv8dhqIxGJRlqoh_wfUYt3NxCVuhY9MoFz2FB0hurxfg6r7KO_AptPI=
iLhv4E_oJBHw33AdiMQt2iX5C2Wb5kZ-mN3dg3SBjYJVHIaCbJ0ezIFvfSPLlKWvIGoqQayunDm=
TOPl0UHnvycoVM5Su9rZ1RNXmnqQQHEzI3eoct173NFWVGD48VanQigPxMDLyxDlh0TQxwZYl49=
ukpTPaSj5fo6TFex7gtuPjK_45D8v5GVkda-mqr1Qu3iui0gTB1G3CGMAY6JMw-05mauUCcBMIn=
bVguoqJRGdLwfJOn9b1jtP7vnUHu17eLjoH01fRRwQirPcWtE0l7eRB6aKKq0HMw )
############################################################
############################################################

--2bd263e9e5b7d43541ca9731e7c0b86c3ccd5a415bd1241747c88d7fefc5
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset=iso-8859-1
Mime-Version: 1.0

<!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>CORONAVIRUS DISEASE 2019 UPDATE (08): MONGOLIA (ULAANBAATAR) BEAVER,<=
br>RESEARCH, 2021<br>******************************************************=
*****************************<br>A ProMED-mail post<br><a href=3D"https://u=
19268662.ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt48tisIijpefK5PNjW-mL-YZGnfgDO=
xU1G3gjwnPSi2Tfv3HA/436/-SGSuWpJTMSKRGT56Xs_kg/h0/0UV_NFkmM4P8gDDQPOUjy00wL=
zl7Kkk9rPmgr-AD3o4">http://www.promedmail.org</a><br>ProMED-mail is a progr=
am of the<br>International Society for Infectious Diseases<br><a href=3D"ht=
tps://u19268662.ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt48tisCT5tpD4Upm3qyMCbc=
YSQvc/436/-SGSuWpJTMSKRGT56Xs_kg/h1/mFsRGThDnRjys_bAyyqlx2pN2tIjVO05Bw-BYOL=
EMhU">http://www.isid.org</a><br><br>Date: Sat 20 Jan 2024=0D<br>Source: CI=
DRAP (Center for Infectious Disease Research & Policy)<br>[edited]=0D<br><a=
 href=3D"https://u19268662.ct.sendgrid.net/ss/c/TLh_csrC34X_iXpbYoMam1B6JfP=
Dl-dNY0xjb47_2RUMcUJK1Y-0t2SU01dHCfwk-_JybvuHbOwmVU4zrDQS9w-b-qfG_B30ucmoO7=
TQBdNqrLSVix8lEtPj8_MgpObZkbzLSRezlEoxqKqG6x5G4w/436/-SGSuWpJTMSKRGT56Xs_kg=
/h2/1kK82D1zCjVhrjch8uRzfiBAyt9f96SlZKfz5DRGlg4">https://www.cidrap.umn.edu=
/covid-19/researchers-outline-covid-19-outbreak-mongolian-beaver-farm</a>=0D=
<br>=0D<br>=0D<br>Yesterday [19 Jan 2024] in Emerging Infectious Diseases<b=
r>[<a href=3D"https://u19268662.ct.sendgrid.net/ss/c/TLh_csrC34X_iXpbYoMam_=
OJx_qp6nDkdVjqCfg9UFks5MUr-C1hnbEIXqA-lDniTH3k1JJPmDFA_cMFt4ngpg/436/-SGSuW=
pJTMSKRGT56Xs_kg/h3/4Ky6EM-a8jEnU47QdM7vb6QY_TJDkg4QlHRpNgZ2u3E">https://ww=
wnc.cdc.gov/eid/article/30/2/23-1318_article</a>], scientists<br>describe a=
 2021 COVID-19 outbreak at a beaver farm in Mongolia.=0D<br>=0D<br>Located =
in the Bayanzurkh district in Ulaanbaatar, the farm raised 32<br>adult beav=
ers and 16 kits in 2021 for conservation purposes. The<br>animals lived in =
a large indoor area separated by waist-high walls.=0D<br>=0D<br>On 6 Aug 20=
21, one of the 7 farm employees tested positive for<br>COVID-19 after exper=
iencing flu-like symptoms. Three days later, the<br>farm reported the death=
 of 2 beavers aged 6 months and 2 years after<br>they exhibited cough, nasa=
l discharge, rasping sounds in the lungs and<br>chest, sluggishness, and fo=
od aversion.=0D<br>=0D<br>On 13 Aug 2021, investigators collected nasal swa=
bs, saliva, and<br>tissue from the 2 dead beavers and obtained nasal sample=
s, saliva, and<br>blood from 7 other beavers exhibiting cough and nasal dis=
charge with<br>pus. Later that week and on 12 Sep 2021, the researchers col=
lected<br>more samples from the same animals and from 2 healthy beavers.=0D=
<br>=0D<br>Four unique mutations spark concern=0D<br>----------------------=
-------------=0D<br>Nearly all (46 of 48) specimens from 9 beavers with cli=
nical signs,<br>including the 2 dead animals, tested positive for COVID-19 =
on<br>polymerase chain reaction (PCR) testing. Serologic testing of 23<br>s=
amples revealed the presence of SARS-CoV-2 antibodies in 15. One<br>beaver =
that didn't show signs of infection also had antibodies.=0D<br>=0D<br>An al=
arming aspect of SARS-CoV-2 infection in animals is that host<br>animals ca=
n maintain the virus and contribute to the emergence in<br>humans of new va=
riants that have accumulated multiple mutations.=0D<br>=0D<br>Five random S=
ARS-CoV-2-positive samples were shipped to Austria for<br>whole-genome sequ=
encing, which identified the delta variant. The delta<br>and alpha variants=
 were circulating among people in Mongolia at the<br>time, and the closest =
related sequences in the beaver samples were<br>from human SARS-CoV-2 in Mo=
ngolia, although they contained 4 novel<br>mutations not found in any publi=
c databases as of November 2023.=0D<br>=0D<br>"An alarming aspect of SARS-C=
oV-2 infection in animals is that host<br>animals can maintain the virus an=
d contribute to the emergence in<br>humans of new variants that have accumu=
lated multiple mutations," the<br>study authors wrote. "Because the emergen=
ce of viruses with mutations<br>not targeted by current SARS-CoV-2 vaccines=
 is a credible possibility,<br>more active surveillance of SARS-CoV-2 infec=
tion in animals should be<br>encouraged to identify the appearance of mutat=
ed viruses."=0D<br>=0D<br>[Byline: Mary Van Beusekom]=0D<br>=0D<br>--=0D<br=
>Communicated by:=0D<br>ProMED=0D<br>via=0D<br>ProMED-MBDS<br><br>[The cita=
tion, abstract and full text of the article referenced above<br>follow:=0D<=
br>=0D<br>Takemura T, Ankhanbaatar U, K Settypalli TB, et al. SARS-CoV-2<br=
>infection in beaver farm, Mongolia, 2021. Emerg Infect Dis. 2024.<br><a hr=
ef=3D"https://u19268662.ct.sendgrid.net/ss/c/TUIVIg4PCmni5tP3Q8lzBRDKvT8Dz6=
46t79_YopI3Q068y4GfL3ZmEoOedutoR7n/436/-SGSuWpJTMSKRGT56Xs_kg/h4/0NOsxzfz__=
N6kvEgBDlBvboTsJ5dyZCRZ0L4bw59KRE">https://doi.org/10.3201/eid3002.231318</=
a>=0D<br>------------------------------------------------------------------=
--------------=0D<br>Abstract=0D<br>--------=0D<br>"We report an outbreak o=
f COVID-19 in a beaver farm in Mongolia in<br>2021. Genomic characterizatio=
n revealed a unique combination of<br>mutations in the SARS-CoV-2 of the in=
fected beavers. Based on these<br>findings, increased surveillance of farme=
d beavers should be<br>encouraged." [References, tables, figures, gray boxe=
s and appendices<br>can be seen at the source URL above]=0D<br>=0D<br>"The =
COVID-19 pandemic that began in 2019 remains uncontained, and<br>fatalities=
 and multiple waves of infection continue to occur worldwide<br>(1). The ca=
usative agent, SARS-CoV-2, has been detected in humans and<br>several anima=
l species, including domestic, wild, and laboratory<br>animals (2,3). Becau=
se SARS-CoV-2 can be transmitted from humans to<br>animals and back to huma=
ns, understanding the dynamics of infection in<br>animals can contribute to=
 the creation of more comprehensive response<br>strategies."=0D<br>=0D<br>"=
We identified SARS-CoV-2 infection in beavers (_Castor fiber_) farmed<br>fo=
r conservation reasons in Mongolia and report on serologic and whole<br>gen=
ome sequence data from this outbreak. The beaver farm, located in<br>the Ba=
yanzurkh district in Ulaanbaatar, Mongolia, reared 32 adults and<br>16 kits=
 in 2021. They were housed indoors in a large area separated by<br>waist-hi=
gh walls, with space for multiple animals. One of the 7<br>employees of the=
 farm had influenza-like symptoms for several days and<br>was diagnosed wit=
h COVID-19 on 6 Aug 2021. On 9 Aug 2021, the beaver<br>farm reported the de=
ath of 2 beavers (one 6 months of age and one 2<br>years of age) after sign=
s of coughing, nasal discharge, rasping on<br>auscultation of the lungs and=
 chest cavity, sluggish movement, and<br>aversion to food. On 13 Aug 2021 r=
esearch investigators collected<br>nasal swabs, saliva, and 7 tissue sample=
s (lung, kidney, liver, heart,<br>spleen, larynx, and tongue from the 2 dea=
d animals. Researchers also<br>collected nasal swab specimens, saliva, and =
blood from 7 other beavers<br>with notable clinical signs of coughing and p=
urulent nasal discharge.<br>Follow-up investigation on 18 or 19 Aug 2021 an=
d on 12 Sep 2021<br>included collection of additional nasal swab specimens,=
 saliva, and<br>blood samples from the same animals as well as from 2 healt=
hy animals<br>(12 Sep 2021 only)."=0D<br>=0D<br>"All samples were transport=
ed to a Biosafety Level 3 facility in<br>Ulaanbaatar and were screened by q=
uantitative reverse transcription<br>PCR according to the Peiris protocol (=
4). The results showed that 46<br>of 48 specimens from 9 animals with clini=
cal signs, including the 2<br>dead animals, tested positive for SARS-CoV-2 =
RNA. Serum was separated<br>from the blood samples by centrifugation (2000 =
x g for 10 min) and<br>stored at -20=B0C until required. The serum samples =
were then subjected<br>to antibody screening by using a commercial ELISA ki=
t (ID Screen<br>SARS-CoV-2 Double Antigen Multi-species ELISA; Innovative D=
iagnostics,<br><a href=3D"https://u19268662.ct.sendgrid.net/ss/c/TLh_csrC34=
X_iXpbYoMam-u-oRULfH40G1dNSa3qBWjtxsM2g6prQp8dgCOHq67kx8YYe0eml-u6YYrSzAi5U=
A/436/-SGSuWpJTMSKRGT56Xs_kg/h5/T4JlQgL5WVrOJXTp2F4WUmLj-4UD7qQYSCBI-kf3JSQ=
">https://www.innovative-diagnostics.comExternal Link</a>). Fifteen of 23<b=
r>samples tested positive and one was intermediate, indicating that all<br>=
animals became antibody positive within one month of confirmation of<br>SAR=
S-CoV-2 RNA positivity. One clinically unremarkable beaver tested<br>positi=
ve for SARS-CoV-2 antibodies, indicating a possible subclinical<br>infectio=
n (Table)."=0D<br>=0D<br>"Phylogenetic tree of SARS-CoV-2 identified from b=
eavers and humans in<br>Mongolia (gray boxes) and reference sequences. The =
circle size<br>indicates the bootstrap values at the node. The vertical bar=
 shows the<br>genetic distance. SARS-CoV-2 lineages are identified at right=
. GenBank<br>accession numbers and date identified are shown for reference<=
br>sequences; the newly obtained sequence data were deposited in GenBank<br=
>(accession nos. OR389473-7)."=0D<br>=0D<br>"We shipped 5 randomly selected=
 quantitative reverse transcription<br>PCR-confirmed SARS-CoV-2-positive RN=
A samples to the Animal Production<br>and Health Laboratory (Seibersdorf, A=
ustria), a joint program of the<br>International Atomic Energy Agency and t=
he Food and Agriculture<br>Organization of the United Nations and subjected=
 them to whole-genome<br>sequencing (Appendix 1; Appendix 2). Based on geno=
type analysis, all 5<br>genome sequences were assigned to the B.1.617.2 lin=
eage, commonly<br>referred to as the delta variant. At the time of sampling=
, alpha and<br>delta variants of SARS-CoV-2 were being identified in humans=
 in<br>Mongolia. The closest related sequences to those we identified in th=
e<br>beavers studied were from human SARS-CoV-2 in Mongolia (GenBank<br>acc=
ession nos. ON008302, OM190617, and OM961234) identified during<br>April-Se=
ptember 2021 (Figure). In addition to 4 mutations in the spike<br>region, t=
he sequences shared 7 amino acid substitutions in open<br>reading frame [OR=
F] 1a, 4 amino acid substitutions in ORF1b, and one<br>amino acid substitut=
ion in nucleocapsid genes. In the beaver<br>sequences, 4 amino acid substit=
utions identified were not in the human<br>isolates from Mongolia: S2500F, =
A3657V in ORF1a and H604Y, T1404M in<br>ORF1b. Although those substitutions=
 have been identified individually<br>in SARS-CoV-2 sequences in GenBank an=
d the GISAID database<br>(<a href=3D"https://u19268662.ct.sendgrid.net/ss/c=
/TLh_csrC34X_iXpbYoMam-VWKv0uxS_3JRJsCN4hWkQl7wG2k0somJhFulZ6qJsz/436/-SGSu=
WpJTMSKRGT56Xs_kg/h6/_ztdGnIijaTMYbT_-T9CTymv7EcK5tAaMUqDOFwxAvk">https://w=
ww.gisaid.orgExternal Link</a>), there are no records of<br>sequences with =
all 4 mutations."=0D<br>=0D<br>"Several cases of SARS-CoV-2 transmission be=
tween humans and animals<br>have already been reported (5-8). An alarming a=
spect of SARS-CoV-2<br>infection in animals is that host animals can mainta=
in the virus and<br>contribute to the emergence in humans of new variants t=
hat have<br>accumulated multiple mutations (7-10). Indeed, the specific<br>=
combination of mutations observed in the beavers we studied has not<br>been=
 found in other SARS-CoV-2 sequences in public databases (as of<br>November=
 2023). This finding suggests that the mutations might have<br>occurred or =
accumulated after the introduction of the virus into the<br>beaver populati=
on. Because the emergence of viruses with mutations not<br>targeted by curr=
ent SARS-CoV-2 vaccines is a credible possibility,<br>more active surveilla=
nce of SARS-CoV-2 infection in animals should be<br>encouraged to identify =
the appearance of mutated viruses. In<br>intensively farmed animals, specie=
s-species and species-humans contact<br>is more frequent than in animals dw=
elling in other environments, which<br>might increase the risk for zoonotic=
 pathogen transmission (2). Thus,<br>implementing more active surveillance =
and infection control strategies<br>is critical to disease prevention and c=
ontainment."=0D<br>=0D<br>An image of beaver can be seen at<br><a href=3D"h=
ttps://u19268662.ct.sendgrid.net/ss/c/TLh_csrC34X_iXpbYoMam1B6JfPDl-dNY0xjb=
47_2RWTCNjJ-7M4Scz2OxpJAUjZdcZ3U1PtSvE2_URB0CqLrcfGYeCM-LwAqTXSCyV1x-8/436/=
-SGSuWpJTMSKRGT56Xs_kg/h7/NeNgSnN-3f_S7v2y7692AeIhxMVrTtwuqiNebjDLN0E">http=
s://www.cidrap.umn.edu/sites/default/files/Beaver.jpg</a>=0D<br>=0D<br>The =
FAO's "SARS-CoV-2 in animals situation update (5 Dec 2023)" is<br>available=
 at<br><a href=3D"https://u19268662.ct.sendgrid.net/ss/c/TLh_csrC34X_iXpbYo=
Mam1f3hHphMwE_gqG9QMefiOcmtemxmzk7MzMcwfnt-RpfJZ7H8UacZ3be25NbH1Ldv3rY_q6Rf=
MDs3kW6LHyZNJF0Z6KJXz97K3-DeXpQ_KhZ/436/-SGSuWpJTMSKRGT56Xs_kg/h8/4cdIgLGhI=
3itCzvEPhHs20l-RP3AtOCzI8h_6qDoIqM">https://www.fao.org/animal-health/situa=
tion-updates/sars-cov-2-in-animals</a>.=0D<br>=20=0D<br>"As the COVID-19 pa=
ndemic continues, the number of mammal species that<br>are susceptible to i=
nfection with SARS-CoV-2 increases. We are at the<br>beginning of a macrocy=
cle that may become the 1st documented case of a<br>viral infection with ex=
ceptional characteristics in terms of<br>host-range susceptibility. Coronav=
irus infections in humans find their<br>origins in viruses circulating in w=
ildlife -- in particular, bats --<br>through cross-species transmission tha=
t often includes intermediate<br>hosts, such as alpacas, palm civets, roden=
ts, cattle, and dromedary<br>camels. Overall, the transmission of pathogens=
 is not unidirectional;<br>ecosystem disruptions and alterations to the hum=
an-wildlife interface<br>also create opportunities for circulating infectio=
us agents to undergo<br>reverse zoonotic transmission, or spillback, into d=
omestic and wild<br>animal species."<br>(<a href=3D"https://u19268662.ct.se=
ndgrid.net/ss/c/irpYa2EQ3F36GLL_pppOEOvPh22EJ2PV8SoTjQ8bLZy9g2sX0oAVxPrkg1R=
xZfbXg3-p5kn4peuzcDxATbriBCKVbhSofupuk9WHN-hH5lw/436/-SGSuWpJTMSKRGT56Xs_kg=
/h9/I2S0sGH3rltCNuN08dMJJy_MA7gDq10mTeIUGOAuy4o">https://academic.oup.com/b=
ioscience/article/73/11/814/7478069</a>) -<br>Mod.TTM<br><br>ProMED map:<br=
>Mongolia: <a href=3D"https://u19268662.ct.sendgrid.net/ss/c/sSnCkKCWBvais3=
EuVAOvgy2WOIX7pp1nXnn4AbwuQ3Z6WbkfhqXYXU-aTMPJ8yTh0uSyOewGlrSD58fmpxZxXQ/43=
6/-SGSuWpJTMSKRGT56Xs_kg/h10/po9iy6y4hlrmaQdfY5mqBBfCbsqFcHHd_CxI9_Z1Ckw">h=
ttps://promedmail.org/promed-post?place=3D8714374,1</a>]<br><br>[See Also:<=
br>COVID-19 update (07): Bangladesh, JN.1, variant of interest<br>http://pr=
omedmail.org/post/20240120.8714357=0D<br>COVID-19 update (06): India, decre=
ase in cases<br>http://promedmail.org/post/20240117.8714284=0D<br>COVID-19 =
update (05): Pakistan, JN.1, variant of interest<br>http://promedmail.org/p=
ost/20240111.8714166=0D<br>COVID-19 update (04): selected locations, JN.1 v=
irology, severity,<br>omicron BA.4.1 in dogs http://promedmail.org/post/202=
40111.8714155=0D<br>COVID-19 update (03): Israel, JN.1, new variant<br>http=
://promedmail.org/post/20240104.8714055=0D<br>COVID-19 update (02): India<b=
r>http://promedmail.org/post/20240103.8714052=0D<br>COVID-19 update (01): C=
ambodia, new JN.1 variant detection<br>http://promedmail.org/post/20240101.=
8714020=0D<br>2023=0D<br>----=0D<br>COVID-19 update (39): Saudi Arabia, JN.=
1 variant, MOH<br>http://promedmail.org/post/20231222.8713858=0D<br>COVID-1=
9 update (38): WHO classifies JN.1 coronavirus strain as<br>'variant of int=
erest' http://promedmail.org/post/20231220.8713808=0D<br>COVID-19 update (3=
7): vaccine comp., selected regions, circ. variants,<br>research http://pro=
medmail.org/post/20231219.8713789=0D<br>COVID-19 update (36): selected coun=
tries/regions, vaccines<br>http://promedmail.org/post/20231212.8713666=0D<b=
r>COVID-19 update (35): Singapore, increase<br>http://promedmail.org/post/2=
0231209.8713618=0D<br>COVID-19 update (34): selected country/region updates=
, variants, WHO<br>http://promedmail.org/post/20231130.8713398=0D<br>COVID-=
19 update (33): country updates, vaccines, vaccine refusal, WHO<br>update h=
ttp://promedmail.org/post/20231105.8713000=0D<br>COVID-19 update (32): upda=
tes, variants, vaccines, antivirals,<br>scientific literature http://promed=
mail.org/post/20231026.8712809=0D<br>COVID-19 update (31): BA.2.86 & EG.5, =
selected regions, vaccines, WHO,<br>global http://promedmail.org/post/20231=
009.8712522=0D<br>COVID-19 update (30): omicron EG.5.1, updates, WHO, globa=
l<br>http://promedmail.org/post/20230815.8711701=0D<br>COVID-19 update (29)=
: updates, wastewater surveillance, transmission,<br>WHO, global http://pro=
medmail.org/post/20230802.8711526=0D<br>COVID-19 update (28): superspread, =
masks, vaccination, WHO, global<br>http://promedmail.org/post/20230724.8711=
339=0D<br>COVID-19 update (27): vaccination, test kit distribution, sequela=
e,<br>WHO, global http://promedmail.org/post/20230717.8711208=0D<br>COVID-1=
9 update (26): animal, North America, wild deer as reservoirs<br>http://pro=
medmail.org/post/20230713.8711124=0D<br>COVID-19 update (25): vaccines, liv=
er disease, sequelae, WHO, global<br>http://promedmail.org/post/20230713.87=
11095=0D<br>COVID-19 update (24): long-term effects, EU.1.1, wild bat, WHO,=
 global<br>http://promedmail.org/post/20230704.8710946=0D<br>COVID-19 updat=
e (23): EU transition plan, viral emission, vacc<br>hesitancy, GBS, WHO htt=
p://promedmail.org/post/20230619.8710662=0D<br>COVID-19 update (22): trends=
, immunity, children, metformin, WHO<br>http://promedmail.org/post/20230612=
.8710546=0D<br>COVID-19 update (21): countries, life expectancy, long COVID=
,<br>research, WHO, global http://promedmail.org/post/20230605.8710423=0D<b=
r>COVID-19 update (20): countries, Paxlovid, vaccine, WHO<br>http://promedm=
ail.org/post/20230530.8710317=0D<br>COVID-19 update (19): countries, vaccin=
e composition, XBB1.16, WHO,<br>global http://promedmail.org/post/20230522.=
8710178=0D<br>COVID-19 update (18): country/regional, vaccine policies, vac=
cination,<br>WHO, global http://promedmail.org/post/20230516.8710088=0D<br>=
COVID-19 update (17): WHO, USA, India, China, XBB.1.16, research,<br>global=
 http://promedmail.org/post/20230508.8709926=0D<br>COVID-19 update (16): XB=
B.1.16, reinfections, microglia, sequelae,<br>WHO, global http://promedmail=
.org/post/20230502.8709789=0D<br>COVID-19 update (15): India, XBB.1.16, fet=
al brain damage, HCW, global<br>http://promedmail.org/post/20230417.8709526=0D=
<br>COVID-19 update (14): countries, vaccines, XBB.1.16, long COVID, WHO<br=
>http://promedmail.org/post/20230407.8709377=0D<br>COVID-19 update (13): In=
dia, surveillance, HCW, rats, infant<br>hospitalizations, WHO, global<br>ht=
tp://promedmail.org/post/20230329.8709196=0D<br>COVID-19 update (12): count=
ries, variants, susceptibility, vaccines,<br>WHO, global http://promedmail.=
org/post/20230321.8709066=0D<br>COVID-19 update (11): country responses, co=
mplications, treatment,<br>WHO, global http://promedmail.org/post/20230312.=
8708900=0D<br>COVID-19 update (10): Hong Kong, XBB.1.5, Iran, UAE, bivalent=
 vacc<br>http://promedmail.org/post/20230308.8708776=0D<br>COVID-19 update =
(09): XBB.1.5, vaccine, WHO<br>http://promedmail.org/post/20230228.8708641=0D=
<br>COVID-19 update (08): countries, immunity, vaccines, treatment, masks,<=
br>WHO, global http://promedmail.org/post/20230219.8708482=0D<br>COVID-19 u=
pdate (07): countries, molnupiravir, vaccines, PACS,<br>cockroach, WHO http=
://promedmail.org/post/20230212.8708331=0D<br>COVID-19 update (06): China, =
demographics, symptoms, PACS, WHO<br>http://promedmail.org/post/20230204.87=
08165=0D<br>COVID-19 update (05): PHEIC continues, WHO<br>http://promedmail=
.org/post/20230130.8708059=0D<br>COVID-19 update (04): PHEIC, China, susp o=
utbreaks, responses,<br>vaccines, global http://promedmail.org/post/2023013=
0.8708043=0D<br>COVID-19 update (03): China, guidelines, vacc, immunity, se=
quelae, WHO<br>http://promedmail.org/post/20230122.8707910=0D<br>COVID-19 u=
pdate (02): China, XBB.1.5, Hong Kong, mAb, pathogenesis,<br>WHO, global ht=
tp://promedmail.org/post/20230115.8707786=0D<br>COVID-19 update (01): China=
, Hong Kong, XBB.1.5, PAHO, treatment,<br>testing, WHO http://promedmail.or=
g/post/20230107.8707667=0D<br>2022=0D<br>----=0D<br>COVID-19 update (193): =
surge, travel restrictions, screening,<br>treatment, WHO http://promedmail.=
org/post/20221230.8707528=0D<br>COVID-19 update (191): omicron BF.7, bivale=
nt vaccines, China, WHO,<br>global http://promedmail.org/post/20221224.8707=
437=0D<br>COVID-19 update (190): China, Australia, vaccines, sequelae, WHO,=
<br>global http://promedmail.org/post/20221219.8707306=0D<br>COVID-19 updat=
e (189): mortality, mAb, intranasal vacc, NPIs,<br>sequelae, WHO, global ht=
tp://promedmail.org/post/20221209.8707146=0D<br>COVID-19 update (188): Chin=
a, omicron BA.2.76, outdoor transmission<br>http://promedmail.org/post/2022=
1130.8706983=0D<br>COVID-19 update (187): boosters, omicron BQ.1.1, Asia, A=
ustralia, WHO,<br>global http://promedmail.org/post/20221129.8706920=0D<br>=
COVID-19 update (185): chr. COVID, bladder, recovery, renal, deaths,<br>WHO=
, global http://promedmail.org/post/20221111.8706665=0D<br>COVID-19 update =
(184): vaccination response, disparity, WHO, global<br>http://promedmail.or=
g/post/20221104.8706549=0D<br>COVID-19 update (183): cardiac events, exerci=
se, US deaths, boosters,<br>WHO, global http://promedmail.org/post/20221028=
.8706414=0D<br>COVID-19 update (182): frontline workers, life expectancy,<b=
r>subvariants, WHO, global http://promedmail.org/post/20221021.8706286=0D<b=
r>COVID-19 update (181): Africa vacc hesitancy, pre-eclampsia, boosters,<br=
>nasal vacc, WHO, global http://promedmail.org/post/20221014.8706143=0D<br>=
COVID-19 update (180): long COVID, neuropsy. illness, Paxlovid,<br>subvaria=
nts, WHO http://promedmail.org/post/20221007.8706007=0D<br>COVID-19 update =
(170): case severity, boosters, physical activity,<br>WHO, global http://pr=
omedmail.org/post/20220825.8705236=0D<br>COVID-19 update (160): vaccine rol=
lout disparities, smell & taste,<br>WHO, global http://promedmail.org/post/=
20220731.8704776=0D<br>COVID-19 update (150): France, omicron 2nd gen varia=
nt, paxlovid, WHO,<br>global http://promedmail.org/post/20220705.8704255=0D=
<br>COVID-19 update (140): Thailand, human to cat to human transmission<br>=
http://promedmail.org/post/20220612.8703819=0D<br>COVID-19 update (130): su=
rveill., cardiac eff., long COVID subtypes,<br>WHO, global http://promedmai=
l.org/post/20220601.8703606=0D<br>COVID-19 update (120): N Korea, pandemic =
exit, youth vaccine, US<br>deaths, WHO http://promedmail.org/post/20220518.=
8703327=0D<br>COVID-19 update (110): mutations, mental health, China, S Afr=
ica,<br>Paxlovid, WHO http://promedmail.org/post/20220505.8703018=0D<br>COV=
ID-19 update (100): vacc. intervals, deaths, long COVID,<br>subvariants, gl=
obal http://promedmail.org/post/20220420.8702717=0D<br>COVID-19 update (90)=
: strategy, 2nd booster, WHO<br>http://promedmail.org/post/20220407.8702454=0D=
<br>COVID-19 update (80): animal, USA, deer, transmission<br>http://promedm=
ail.org/post/20220325.8702212=0D<br>COVID-19 update (70): case count, UK, B=
A.2, USA, WHO, global<br>http://promedmail.org/post/20220312.8701940=0D<br>=
COVID-19 update (60): animal, China, origin, research<br>http://promedmail.=
org/post/20220227.8701690=0D<br>COVID-19 update (50): Hong Kong, estrogen r=
isk, maternal vaccine<br>benefits, WHO http://promedmail.org/post/20220217.=
8701501=0D<br>COVID-19 update (40): Denmark, rosemary, pregnancy, stroke, W=
HO<br>http://promedmail.org/post/20220205.8701276=0D<br>COVID-19 update (30=
): variants in immuno-comp., stability, endemic,<br>WHO http://promedmail.o=
rg/post/20220126.8701074=0D<br>COVID-19 update (20): Africa vacc., Taiwan, =
waning immunity,<br>persistence, global http://promedmail.org/post/20220117=
.8700915=0D<br>COVID-19 update (10): animal, omicron origin statement, OIE<=
br>http://promedmail.org/post/20220110.8700763=0D<br>COVID-19 update (01): =
omicron severity & changes, Germany, T-cell<br>reactivity http://promedmail=
.org/post/20220101.8700616]<br>............................................=
.....ttm/st/may/jh<br></body>
</html><!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>*##########################################################*<br>*****=
*******************************************************<br>ProMED makes eve=
ry effort to verify the reports that are posted, but the accuracy<br>and co=
mpleteness of the information, and of any statements or opinions based<br>t=
hereon, are not guaranteed. The reader assumes all risks in using informati=
on<br>posted or archived by ProMED. ISID and its associated service provide=
rs shall not<br>be held responsible for errors or omissions or held liable =
for any damages incurred<br>as a result of use or reliance upon posted or a=
rchived material.<br>******************************************************=
******<br>Donate to ProMED. Details available at: https://isid.networkforgo=
od.com/projects/79924-invest-in-the-mission.<br>***************************=
*********************************<br>Visit ProMED's website at https://www.=
promedmail.org/.<br>Submit all items for posting via the ProMED website at =
https://promedmail.org/submitinfo/.<br>If you have any questions or need su=
pport, please contact us via the ProMED website at  https://promedmail.org/=
support/.<br>You may subscribe/unsubscribe at  https://isid.org/promedmail-=
subscribe/.<br><div><a href=3D"https://u19268662.ct.sendgrid.net/asm/?user_=
id=3D19268662&amp;data=3DLnf8WbiB-BSp1lEdedFtvk4_L4-E9azacMvmjLpo_DZoMDAwdT=
AwMKXB3AKDS3wbrCkyM-oRVkxES3qkbK321OhJOQmG9dISsyzioppB_TvVXYSn-S9zBFYyw-ygo=
nLgj7t02BT-RCEw7eJsp0bQv71l-Sa3tWEr_yA3gHORZ0iNOZ0yXDxglx5U9UetLprx727kzfPv=
BCHNgdJR-7jEGbHwD73th2dqWjxjo1I-C8al_i3O60HDbGYi594qPozBadFk9f-ql_CZ2r9uel3=
T4s8p_vL8WCS63glBEZKAUssX8m1PtXA7Vd1cqC1GGUuNxXu8yG5sx9jN3v3DpPljRs1-ej1-UW=
HSQLuCT0jRu6jLOiuWs9XD7tSf7c5YflxYTAcqzeMiajaLVvmNiL_u0Fjvl55TBznBsCXcBXbj8=
WG5zUBAZmmLih7NdiCUcjBjVz2DWiHP_FqvKVK3VYtOLRZWCVyvAP4ov3zpmNbCrX6-V-Yw83BK=
0PfdrxpDOsYQx-LrpSiwS9vBd49L7tsJjvEJFsfggjNv4gIW6j1cxqZ73EkysrpC9ovJA57BwrF=
_UfF1p3P7QgtSMP0GADKkt6stvIC5VMsqOoAIkVXMZ-OgBcC9_h_vgCVK6fON9uH2KLApTJjpn5=
hEUMKQGH-RtEDqZjZdicIC_gj4ngBuTfw1a8jzltJj2FzvG5rggvwwiHvJzOlnXUonBuFfqWT5g=
JWL0D6H_Nn7EOzycSwzjnaVxTqmKSEiRdBaHiBpsdvXOmOZvTlboM4hUvXK39Tw1b1l3QUyJllG=
jHBW1iB1ZfcEpnpwbb6hA4em8znf__0iJ0BYIpCVzYHa6IZxpOgTJSBUWoaBDUHNhq0PiM-66Sn=
2cad_9W-2buRlwxbYWd9Dm7RvKvFYjv8dhqIxGJRlqoh_wfUYt3NxCVuhY9MoFz2FB0hurxfg6r=
7KO_AptPIiLhv4E_oJBHw33AdiMQt2iX5C2Wb5kZ-mN3dg3SBjYJVHIaCbJ0ezIFvfSPLlKWvIG=
oqQayunDmTOPl0UHnvycoVM5Su9rZ1RNXmnqQQHEzI3eoct173NFWVGD48VanQigPxMDLyxDlh0=
TQxwZYl49ukpTPaSj5fo6TFex7gtuPjK_45D8v5GVkda-mqr1Qu3iui0gTB1G3CGMAY6JMw-05m=
auUCcBMInbVguoqJRGdLwfJOn9b1jtP7vnUHu17eLjoH01fRRwQirPcWtE0l7eRB6aKKq0HMw" =
target=3D"_blank" class=3D"Unsubscribe--unsubscribePreferences" style=3D"fo=
nt-family:sans-serif;text-decoration:none;">Unsubscribe Preferences</a></di=
v><br>############################################################<br>#####=
#######################################################<br><br><img src=3D"=
https://u19268662.ct.sendgrid.net/ss/o/LbtalBvHhFtzyiegKfBhew/436/-SGSuWpJT=
MSKRGT56Xs_kg/ho.gif" alt=3D"" width=3D"1" height=3D"1" border=3D"0" style=
=3D"height:1px !important;width:1px !important;border-width:0 !important;ma=
rgin-top:0 !important;margin-bottom:0 !important;margin-right:0 !important;=
margin-left:0 !important;padding-top:0 !important;padding-bottom:0 !importa=
nt;padding-right:0 !important;padding-left:0 !important;"/></body>
</html>
--2bd263e9e5b7d43541ca9731e7c0b86c3ccd5a415bd1241747c88d7fefc5--
